Dr. Harpreet Singh is Co-Founder, Chief Executive Officer and Member of the Board at Immatics (NASDAQ: IMTX), a clinical-stage biotechnology company and the global leader in precision targeting of PRAME. PRAME is a target expressed in more than 50 cancers and Immatics has the broadest PRAME franchise with the most PRAME indications and modalities, spanning cell therapies and bispecifics.
Dr. Harpreet Singh brings together leadership experience, scientific expertise and innovation in T-cell based immunotherapy of advanced solid cancers. He has played a critical role in developing Immatics from a start-up into a global, publicly listed biopharma enterprise, leading a team of more than 500 people based in the US and Germany, committed to making a meaningful impact on the lives of patients with cancer.
Dr. Singh holds a PhD in immunology from the University of Tuebingen, Germany.